Alvotech Enrolls First Patient in Clinical Phase III Study Involving Biosimilar Version of HUMIRA(R)

Alvotech's AVT02 is being developed as a biosimilar of the HUMIRA® high-concentration (100mg/mL) product, expected to be more convenient for patients, compared to biosimilar competitors 400 participants to be enrolled in Phase III study at 30 sites ... Biopharmaceuticals, Generics, Dermatology Alvotech, HUMIRA, biosimilar, plaque psoriasis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news